Business Wire

Shionogi to Present Clinical Data on Lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the Liver (EASL)

Share

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019. Lusutrombopag was granted marketing authorisation by the European Commission (EC) on February 18, 2019 for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures. It has already been approved for use in Japan1 and the US where it is marketed under the brand name Mulpleta®2.

All poster presentations will be displayed in Reed Messe Wien Exhibition & Congress Center Hall B on Saturday, April 13, 2019 from 9:00 am to 5:00 pm Central European Time (CET). The research will be presented in the Cirrhosis and Complications poster area and will include the following:

  • Poster SAT 002: Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing an Invasive Procedure: Pooled Safety Analysis from 3 Studies
    Presenter: Nezam Afdhal
  • Poster SAT 003: Real-World Data Demonstrate Safety and Effectiveness of Lusutrombopag in Chronic Liver Disease Patients with Thrombocytopenia Undergoing Planned Invasive Procedures: Interim Analysis
    Presenter: Nezam Afdhal
  • Poster SAT 006: Efficacy of Oral Thrombopoietin Receptor Agonist Lusutrombopag in Chronic Liver Disease by Underlying Disease Aetiology
    Presenter: Naim Alkhouri
  • Poster SAT 038: Lusutrombopag for Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Who Are Undergoing Planned Invasive Procedures: Pooled Safety Analysis of Bleeding-Related Adverse Events
    Presenter: Edoardo G. Giannini

About Thrombocytopenia in Chronic Liver Disease
Thrombocytopenia is defined as a platelet count of less than 150,000/µL. CLD-associated thrombocytopenia may be caused by multiple factors including splenic sequestration and decreased production of TPO. It is the most common hematologic complication of CLD3,4,5, with studies suggesting that it occurs in up to 78% of patients with cirrhosis.6 Severe thrombocytopenia (platelet count of less than 50,000/µL) is less common, occurring in up to 11% of patients.7 Patients with CLD and thrombocytopenia are at increased risk for bleeding, requiring recurrent platelet transfusions, increased ambulatory visits and inpatient hospital stays compared with patients with CLD without thrombocytopenia.7,8 There is evidence that the annual health care cost of a CLD patient with thrombocytopenia is more than three times that of a CLD patient without thrombocytopenia.8 In addition to the potential of thrombocytopenia, especially severe thrombocytopenia (platelet count less than 50,000/µL), which increases surgical or traumatic bleeding, it may also significantly complicate routine diagnostic procedures and patient care, such as liver biopsy and medically indicated or scheduled procedures for cirrhotic patients, resulting in delayed or cancelled curative treatment.9

About lusutrombopag
Lusutrombopag is a once-daily, orally administered, small molecule TPO receptor agonist that triggers the production of endogenous platelets by interacting with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.

On February 18, 2019, lusutrombopag received marketing authorisation by the EC for the treatment of severe thrombocytopenia in adult patients with CLD undergoing invasive procedures. Prior to this, lusutrombopag was approved by the Ministry of Health, Labour and Welfare in Japan in September 2015 for the improvement of thrombocytopenia associated with CLD in patients undergoing an elective invasive procedure, and by the U.S. Food and Drug Administration (FDA) on July 31, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. It is currently being commercialised in Japan and the US, where it is marketed under the brand name Mulpleta®.

About Shionogi
Shionogi & Co., Ltd. (“Shionogi”) is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For more information on Shionogi, please visit www.shionogi.co.jp/en/.

Forward Looking Statement
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

References:
1. Japanese Approval of Lusutrombopag. Available at: http://www.info.pmda.go.jp/go/pack/3399010F1022_1_02/ . Last accessed April 2019
2. FDA New Drug Application Approval Letter. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000Approv.pdf . Last accessed April 2019
3. Giannini EG. Aliment Pharmacol Ther. 2006; 23(8):1055-1065.
4. Koruk M, et al. Hepatogastroenterology. 2002; 49(48):1645-1648.
5. Aref S, et al. Hematology. 2004; 9(5/6):351-356.
6. Peck-Radosavljevic M. Liver Int. 2017; 37(6):778-793.
7. de Gottardi, A. et al. Clin Gastroenterol Hepatol. 2009;7(8):906-9
8. Poordad F, et al. J Med Econ. 2012; 15:112-124.
9. Hayashi H, et al. World J Gastroenterol. 2014; 20: 2595-2605.

Lusutrombopag Summary of Product Characteristics is available at: https://www.ema.europa.eu/en/documents/product-information/lusutrombopag-shionogi-epar-product-information_en.pdf

Contact information

Corporate Communications, Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885

Shionogi Inc. U.S. Media Contact
Barbara Kalavik
Telephone: +001973-307-3373

Shionogi Europe Media Contact
Dr. Mark Hill
Telephone: +44-7387-104-907

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetMedia Group takes over the management of financial platform Investing.com's European advertising space23.7.2019 08:07:00 CESTPress release

NetMedia Group, media B2B leader in Europe in the world of business information, and Investing.com, second largest financial services and information platform in Europe, are to form a partnership, with NetMedia Group handling the sales of advertising space for Investing.com. With average traffic of over 21 million unique users totaling over 175 million sessions in 31 countries, Investing.com is one of the top three global financial websites and has the most downloaded financial management app. For Investing.com, the aim of the new partnership is to maximize digital advertising revenue through the NetMedia Group's European teams. NetMedia Group's goal is to expand its advertising services by offering a new vertical market for finance, in order to boost the range of services it has available to decision-makers for upper socio-professional target groups. About NetMedia Group: NetMedia Group is a B2B media group located in five countries across Europe; it employs nearly 150 staff members a

Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market23.7.2019 08:00:00 CESTPress release

Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1] “The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising,

LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets23.7.2019 08:00:00 CESTPress release

LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series of antibodies. These 565 antibodies were selected from among thousands tested and identified to be the best performing reagents for immunohistochemical detection of 200 high-value cancer targets in formalin-fixed paraffin-embedded human tissues. Antibody validation has become an industry roadblock as thousands of antibodies have become available to customers who face difficult choices in determining which antibodies are the best performers for each application, including immunohistochemistry, flow cytometry, ELISA, Western blot, or immunofluorescence. Antibodies that perform well in one assay, such as IHC, may not be the most specific reagent for another assay, such as flow cytometry. “Identifying the optimal reagents to use in their experiments is a pain point for researchers,” said LSBio CEO Heather Holemon. “There is a tremendous need to identify

IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 201923.7.2019 07:00:00 CESTPress release

IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2019 financial results to investors on Tuesday July 30, 2019. Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time). For more information, please refer to our website: https://investors.idemia.com/ About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whet

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g